Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the companys Phase III ATTAIN-2 study
With FDA approval, resmetirom, a liver-targeted thyroid hormone receptor- (THR) selective agonist, changes the MASH drug development landscape
The safety and efficacy of Semaglutide GLP-1 have been evaluated in clinical trials for up to two years, and ongoing studies continue to assess its long-term effects
Abdominal vagal signalling: a novel role for cholecystokinin in circulatory control
At a concentration of 10 mM, exposure was found to cause profound intracellular Ca 2+ overload and significant Ca 2+ -dependent lytic cell death
US$ 21.11
US$ 22.29
US$ 22.82
US$ 29.66
US$ 21.57
